Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057549 · ClinicalTrials.gov registry record · Phase 4
Haloperidol vs Conventional Therapy for Gastroparesis
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT02057549: Clinical Trial Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
NCT02057549 is a Phase 4 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 36 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02057549, a Phase 4 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
Randomized controlled trial comparing haloperidol combined with conventional therapy and conventional therapy alone in patients with symptomatic gastroparesis.
Interventions
- DRUG Haloperidol
- DRUG Conventional Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-11 |
| Phase | Phase 4 |
Why NCT02057549 stopped before completion
NCT02057549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Haloperidol is the first listed.
NCT02057549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02057549 about?
NCT02057549 is a clinical study titled "Haloperidol vs Conventional Therapy for Gastroparesis". Randomized controlled trial comparing haloperidol combined with conventional therapy and conventional therapy alone in patients with symptomatic gastroparesis.
What is the current status of trial NCT02057549?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2012-11. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02057549?
The interventions under investigation include: Haloperidol (DRUG), Conventional Therapy (DRUG).
Who is sponsoring clinical trial NCT02057549?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02057549's enrollment target sits among peer trials
36 1490th of 2000 higher than 495 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia